Publication

Article

Oncology Treatment Pathways®

November 2022
Volume

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Download Issue PDF
Articles in this issue
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Related Videos
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Related Content
FDA
November 19th 2024

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
November 15th 2024

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Vinayak Venkataraman, MD
November 11th 2024

Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

DLL3-TOPAbody
November 8th 2024

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors